ReviewInternational journal of chronic obstructive pulmonary disease2026
Chronic Obstructive Pulmonary Disease in Singapore: Current Perspectives on Prevalence, Disease Burden, and Treatment.
Review in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) represents a significant global health challenge, affecting millions worldwide, with an estimated prevalence of 5.9% specifically for Singapore, and a projected increase driven by population aging. Despite comprehensive healthcare infrastructure, COPD remains underdiagnosed and undertreated in Singapore. Real-world evidence indicates that most patients present with moderate-to-severe disease and exhibit high rates of comorbidities, including cardiovascular disorders, diabetes, and bronchiectasis, which complicate COPD management and increase healthcare utilization. Smoking remains the predominant risk factor, although non-smoking phenotypes linked to prior tuberculosis, biomass exposure, and environmental allergens are increasingly recognized. COPD imposes a significant economic burden, primarily driven by hospitalizations, and disproportionately affects certain ethnic groups, underscoring the need for culturally tailored interventions. Current treatment strategies for moderate-to-severe COPD emphasize smoking cessation, pulmonary rehabilitation, and inhaled bronchodilator therapy; however, substantial gaps persist, with frequent exacerbations despite triple therapy (long-acting β2-agonists and long-acting muscarinic antagonists along with inhaled corticosteroids) and inappropriate oral corticosteroid use contributing to adverse outcomes. Recent advances in biologic therapies targeting type 2 inflammation, notably dupilumab, approved in Singapore in 2025 offer promising options for patients with uncontrolled COPD characterized by elevated blood eosinophils. Emerging biomarkers, such as fractional exhaled nitric oxide, may further refine patient selection for precision therapy. This review focuses on the current evidence on COPD epidemiology, clinical characteristics, risk factors, treatment patterns, and evolving therapeutic approaches in Singapore, highlighting opportunities to optimize patient care through early diagnosis and adoption of novel biologics to improve outcomes in this heterogeneous population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.